Key facts
- KYinno Biotechnology’s last known valuation is $68.3M (Oct 2021).
- It has raised $59.0M; the latest was Later Stage VC ($34.5M) in Feb 2025.
- Notable investors include Beijing State-owned Capital Operation and Management, Renai Capital, BioTrack Capital, China Everbright, Guochun Li — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for KYinno Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for KYinno Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KYinno Biotechnology
Developer of oncology drugs intended to accelerate cancer drug discovery and development. The company offers immune treatments against cancer, antibody discovery workflows, engineered cellular systems, and next-generation kinase inhibitor design, dedicated to oncology drug discovery and customized product development, enabling these groups to progress their scientific programs effectively.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2017
- Employees
- 130
- Website
- kyinno.com/
- Ownership
- Privately Held (backing)
KYinno Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KYinno Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KYinno Biotechnology in its N-PORT filings yet. We sweep new filings monthly.